Clinical Research Directory

Inclusion Criteria: * Patients with stage III-IV HER2 negative breast cancer treated with primary or salvage therapy and now have: * No evidence of disease (NED), or * Stable bone only disease * Patients who have completed standard of care and recovered with mild to no residual toxicity from recent therapy * Patients must be at least 28 days post cytotoxic chemotherapy, and/or monoclonal antibody therapy (excluding bone-directed therapy), prior to enrollment * Patients must be at least 28 days post systemic steroids prior to enrollment * Patients on bisphosphonates, denosumab, and/or endocrine therapy are eligible * Patients must have Eastern Cooperative Oncology Group (ECOG) performance status score of =\< 1 * Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment * Estimated life expectancy of more than 6 months * White blood cells (WBC) \>= 3000/mm\^3 (within 30 days of first vaccination) * Lymphocyte count \>= 800/mm\^3 (within 30 days of first vaccination) * Platelet count \>= 75,000/mm\^3 (within 30 days of first vaccination) * Hemoglobin (Hgb) \>= 10 g/dl (within 30 days of first vaccination) * Serum creatinine \<= 1.2 mg/dl or creatinine clearance \> 60 ml/min (within 30 days of first vaccination) * Total bilirubin \<= 1.5 mg/dl (within 30 days of first vaccination) * Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) \<= 2 times upper limit of normal (ULN) (within 30 days of first vaccination) * Blood glucose \< 1.5 ULN (within 30 days of first vaccination) * All patients who are having sex that can lead to pregnancy must agree to contraception for the duration of study Exclusion Criteria: * Patients with any of the following cardiac conditions: * Symptomatic restrictive cardiomyopathy * Unstable angina within 4 months prior to enrollment * New York Heart Association functional class III-IV heart failure on active treatment * Symptomatic pericardial effusion * Patients at risk for gastrointestinal bleeding (example: peptic ulcer disease, prolonged daily non-steroidal anti-inflammatory use) * Patients with any seizure disorder * Patients with any contraindication to receiving rhuGM-CSF based products * Patients with any clinically significant autoimmune disease uncontrolled with treatment * Patients who are simultaneously enrolled in any other treatment study * Patients who are pregnant or breastfeeding